《大行》高盛上調百濟神州(ONC.US)ADR目標價至378.2美元 維持「買入」評級
高盛發表報告,指百濟神州(06160.HK)(ONC.US)第二季產品銷售按年升41%至13億美元,勝該行及市場預期,受美國市場百悅澤銷售在首季低基數下按季強勁反彈21%至6.84億美元,該銷售增長歸因於產品在美國市場的領導地位加強及溫和受惠於小型生物科技公司的產品淨定價,以及在歐盟及全球其他市場的市佔增加,內地銷售額亦按年升31%符合預期。百澤安季度銷售增長加速增長,並持續在全球市場擴張。公司將全年收入指引下限從49億美元上調至50億美元。
該行上調對公司今年至2027年每股盈利預測,反映公司第二季業績,公司上調財務指引、調整對百悅澤今年銷售預測、加入對百赫安今年銷售預估及排除今明兩年關稅影響。該行更新對該股A/H股溢價價差,對百濟神州ADR目標價由352.98美元上調至378.2美元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.